Novartis Phase Ii/Iii Study Of Tafinlar+Mekinist Demonstrates Unprecedented Efficacy In Paediatric Patients With Braf V600 Low-Grade Gliomas

Novartis Announced Tafinlar (Dabrafenib) + Mekinist (Trametinib) Significantly Improved Efficacy In Patients Ages 1 To 17 Years Old With Braf V600 Paediatric Low-Grade Glioma (Plgg) Requiring First Systemic Treatment Compared To Chemotherapy, The Current Standard-Of-Care For These Patients. In This Study, Patients Randomized To Receive Tafinlar + Mekinist Experienced A Statistically Significant Overall Response Rate (Orr) Of 47% (Ci: 35-59%) Compared To 11% (Ci: 3-25%, P<0.001) For Those Randomized To Receive Chemotherapy. A New Liquid Formulation Of Tafinlar + Mekinist That Can Be Easier To Administer Than Chemotherapy Was Used In This Trial. The Data Highlighted As Part Of An Official Press Briefing And Oral Presentation At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting (Abstract #Lba2002).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!